<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651153</url>
  </required_header>
  <id_info>
    <org_study_id>UP0092</org_study_id>
    <secondary_id>2020-003356-32</secondary_id>
    <nct_id>NCT04651153</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)</brief_title>
  <official_title>A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate the safety and tolerability of single&#xD;
      ascending doses of UCB7853 in healthy male study participants and to evaluate the safety and&#xD;
      tolerability of multiple ascending doses of UCB7853 administered in study participants with&#xD;
      Parkinson's Disease (PD)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events (TEAEs) in healthy male participants</measure>
    <time_frame>From Day 1 to the End of Study Visit (Day 141), Part 1)</time_frame>
    <description>A treatment-emergent Adverse Event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events (TEAEs) in participants with Parkinson's Disease</measure>
    <time_frame>From Day 1 to the End of Study Visit (Day 197), Part 2</time_frame>
    <description>A treatment-emergent Adverse Event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants</measure>
    <time_frame>Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1</time_frame>
    <description>Cmax = Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of UCB7853 in serum after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease</measure>
    <time_frame>Samples will be taken from Day 57 to the End of Study Visit (Day 197), Part 2</time_frame>
    <description>Cmax = Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants</measure>
    <time_frame>Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1</time_frame>
    <description>AUC = Area under the concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants</measure>
    <time_frame>Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1</time_frame>
    <description>AUC(0-t) = Area under the concentration-time curve from time 0 to time t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) of UCB7853 in serum after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease</measure>
    <time_frame>Samples will be taken from Day 57 to Day 85, Part 2</time_frame>
    <description>AUC(0-t) = Area under the concentration-time curve from time 0 to time t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants</measure>
    <time_frame>Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1</time_frame>
    <description>tmax = Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of UCB7853 in serum after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease</measure>
    <time_frame>Samples will be taken from from Day 57 to the End of Study Visit (Day 197), Part 2</time_frame>
    <description>tmax = Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants</measure>
    <time_frame>Samples will be taken from Day 1 to the End of Study Visit (Day 141), Part 1</time_frame>
    <description>t1/2 = Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of UCB7853 after intravenous infusion of single ascending doses in healthy male participants</measure>
    <time_frame>Samples will be taken from from Day 1 to the End of Study Visit (Day 141), Part 1</time_frame>
    <description>CL = Total body clearance of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of UCB7853 after intravenous infusion of multiple ascending doses in study participants with Parkinson's Disease</measure>
    <time_frame>Samples will be taken from from Day 57 to Day 85, Part 2</time_frame>
    <description>CL = Total body clearance of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz of UCB7853 in serum after intravenous infusion of single ascending doses in healthy male participants</measure>
    <time_frame>Samples will be taken from from Day 1 to the End of Study Visit (Day 141), Part 1</time_frame>
    <description>Vz = Volume of distribution during terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF/serum UCB7853 concentration ratio on Day 7 (Part 1)</measure>
    <time_frame>Day 7 (Part 1)</time_frame>
    <description>CSF = Cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF/serum UCB7853 concentration ratio on Day 63 (Part 2)</measure>
    <time_frame>Day 63 (Part 2)</time_frame>
    <description>CSF = Cerebrospinal fluid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>UCB7853</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Single intravenous infusion of UCB7853 Part 2: Multiple intravenous infusions of UCB7853 at pre-specified time-points</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1: Single intravenous infusion of Placebo Part 2: Multiple intravenous infusions of Placebo at pre-specified time-points</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB7853</intervention_name>
    <description>Subjects will receive UCB7853 at pre-specified time-points.</description>
    <arm_group_label>UCB7853</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive Placebo at pre-specified time-points.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1 (healthy participants):&#xD;
&#xD;
          -  Participant must be male and 18 to 55 years of age inclusive&#xD;
&#xD;
          -  Body weight within 50 kg to 110 kg and body mass index (BMI) within the range 18.0 to&#xD;
             30.0 kg/m^2 (inclusive)&#xD;
&#xD;
          -  Participant must be healthy as determined by medical evaluation, including medical&#xD;
             history, physical examination, laboratory tests, and cardiac monitoring&#xD;
&#xD;
          -  Participant has clinical laboratory test results within the reference ranges of the&#xD;
             laboratory&#xD;
&#xD;
        Part 2 (participants with Parkinson's Disease):&#xD;
&#xD;
          -  Participant must be 40 to 80 years of age, inclusive, at the time of signing the&#xD;
             informed consent form (ICF)&#xD;
&#xD;
          -  Participant may be male or female&#xD;
&#xD;
          -  Participant must have body weight of between 50 and 110 kg and a body mass index&#xD;
             within the range of 18 to 32 kg/m^2 (inclusive)&#xD;
&#xD;
          -  Participant must have a clinical diagnosis of Parkinson's disease (PD) according to&#xD;
             the Movement Disorders Society criteria. The following diagnostic criteria must be&#xD;
             met: Bradykinesia AND at least ONE of the following: muscular rigidity or resting&#xD;
             tremor&#xD;
&#xD;
          -  Participant must have a Hoehn and Yahr Stage of â‰¤3&#xD;
&#xD;
          -  Participant must be either untreated, or treated with a stable regimen (at least 4&#xD;
             weeks prior to Baseline Visit) of antiparkinsonian drugs and is expected to remain on&#xD;
             this regimen for the duration of the study&#xD;
&#xD;
          -  Participant must be in good physical and mental health, in particular not affected by&#xD;
             any neurological disorder other than Parkinson's disease (PD), in the opinion of the&#xD;
             Investigator, determined on the basis of medical history and a general clinical&#xD;
             examination at Screening&#xD;
&#xD;
          -  Participant has clinical laboratory test results within the reference ranges of the&#xD;
             laboratory&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part 1 (healthy participants):&#xD;
&#xD;
          -  Participant has a history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrinological, hematological, pancreatic, musculoskeletal,&#xD;
             genitourinary, immunological, dermatological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             constituting a risk when taking the study intervention; or interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  Participant has a known hypersensitivity to any components of the study medication or&#xD;
             comparative drugs&#xD;
&#xD;
          -  Participant has any clinically relevant abnormal findings in physical examination,&#xD;
             laboratory tests, or vital signs, which, in the opinion of the Investigator, may place&#xD;
             the participant at risk because of participation in the study&#xD;
&#xD;
          -  Participant has any clinically relevant brain magnetic resonance imaging (MRI)&#xD;
             abnormality at Screening&#xD;
&#xD;
        Part 2 (participants with Parkinson's Disease):&#xD;
&#xD;
          -  Participant has a diagnosis of a significant Central nervous system (CNS) disease&#xD;
             other than PD or history of epilepsy or seizure disorder other than febrile seizures&#xD;
             as a child&#xD;
&#xD;
          -  Study participant has a history of levodopa-induced motor fluctuations or dyskinesia&#xD;
             expected to interfere with his/her ability to participate in the study&#xD;
&#xD;
          -  Participant has a known hypersensitivity to any components of the study medication or&#xD;
             comparative drugs&#xD;
&#xD;
          -  Study participant has had prior surgical treatment for PD involving intracranial&#xD;
             surgery or implantation of a device (including deep brain stimulation) or duodopa&#xD;
&#xD;
          -  Participant has any clinically relevant abnormal findings in physical examination&#xD;
             (other than symptoms of PD), laboratory tests, or vital signs, which, in the opinion&#xD;
             of the Investigator, may place the participant at risk because of participation in the&#xD;
             study&#xD;
&#xD;
          -  Participant has any clinically relevant brain MRI abnormality at Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>001844599</phone>
    <phone_ext>2273</phone_ext>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Up0092 101</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

